Northbrook, IL, United States
Northbrook, IL, United States

Time filter

Source Type

News Article | November 8, 2016
Site: marketersmedia.com

— The report "Sepsis Diagnostics Market by Technology (Molecular Diagnostics, Microbiology, Immunoassay), Product (Instrument, Blood Culture Media), Method (Conventional & Automated), Usability (Laboratory & POC), Pathogen (Bacterial & Fungal) - Global Forecast to 2021", analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the world (RoW). On the basis of products, the global sepsis diagnostics market is segmented into 4 broad categories, namely, blood culture media, assay kits & reagents, instruments, and software. The blood culture media market is estimated to command the largest share of the global sepsis diagnostics market in 2016. The large share of this segment can be attributed to the high use of blood culture testing as the standard diagnostic method for the diagnosis and identification of sepsis. The global assay kits & reagents segment, on the other hand, is expected hold the second largest share in the market owing to the increasing adoption of assay based kits and growing approvals for assay kit products across the globe. Based on technology, the global sepsis diagnostics market is segmented as microbiology, immunoassays, molecular diagnostics, and flow cytometry. The global molecular diagnostic segment is expected to grow at the highest CAGR from 2016 to 2021. Its growth can be attributed to the increasing inclination of physicians and patients towards use of rapid diagnostic products for accurate and quick identification and diagnosis of sepsis. The global sepsis diagnostics market is also divided into two segments by method– conventional diagnostics and automated diagnostics. Furthermore, on the basis of usability, the sepsis diagnostics market is categorized into laboratory testing and point-of-care testing. The sepsis diagnostics market on the basis of pathogen is segmented into bacterial sepsis, fungal sepsis, and other infectious pathogens (viral and parasitic infection). The bacterial sepsis segment is expected to account for a larger share (85.7%) of the sepsis diagnostics market in 2016. Key factors such as rising geriatric population, growing number of surgical procedures, high incidence of hospital-acquired infections, and growth in the number of product approvals are supporting the growth of this market. On the other hand, lack of standard protocols and awareness and shortage of skilled staff are the major challenges in this market. As of 2016, North America holds the largest share of the global sepsis diagnostics market, followed by Europe. However, the Asia-Pacific market is expected to grow at the highest CAGR of 11.9% from 2016 to 2021. A number of factors such as increasing number of surgical procedures, growing number of clinical studies, developing healthcare infrastructure, and rising focus of global players in this region are propelling the growth of the Asia-Pacific sepsis diagnostics market. bioMérieux SA (France), T2 Biosystems, Inc. (U.S.), Cepheid (U.S.), Thermo Fisher Scientific Inc. (U.S.), Nanosphere, Inc. (U.S.), Abbott Laboratories, Inc. (U.S.), Roche Diagnostics Limited (Switzerland), Becton, Dickinson and Company (U.S.), Bruker Corporation (U.S.), and Beckman Coulter, Inc. (U.S.) are some of the key players operating in the sepsis diagnostics market. For more information, please visit http://www.marketsandmarkets.com/requestsample.asp?id=92673155


The blood culture test market is categorized on the basis of methods, products, applications, end users, and regions. The global blood culture tests market is projected to reach USD 4,768.9 million by 2021 from USD 3,252.6 million in 2016, at a CAGR of 8.0%. Major factors contributing to the growth of this market include growing number of sepsis cases and high cost of treatment, increase in prevalence of infectious diseases, rapidly rising aging population, increase in product approvals and launches, increase in demand for rapid diagnostic techniques, and high incidence of bloodstream infections. Complete report on Blood Culture Tests Market spread across 249 Pages, Profiling 11 Companies and Supported with 300 Tables and 50 Figures is now available at http://www.reportsnreports.com/reports/377270-blood-culture-test-market-by-method-manual-automated-product-consumables-instrument-application-aerobic-anaerobic-yeast-fungi-end-user-hospital-reference-laboratory-clinical-laboratory-academic-research-institute-forecast-to-2019.html The relatively untapped Asian region provides an array of growth opportunities for blood culture test market. A large population base, rapid urbanization, increase in blood stream infection (BSI), rising prevalence of infectious diseases, rising aging population, increasing product availability, and technological advancements are some of the factors responsible for growth of this market. North America dominates the blood culture tests market in 2016, followed by Europe. However, Asia is projected to grow at the highest CAGR during the forecast period, owing to high incidence of sepsis and government initiatives to increase awareness on the disease, increasing demand for effective diagnostic techniques, rising awareness about early disease diagnosis, increasing adoption of advanced technologies, rapid rise in geriatric population, and growing regulatory approvals & availability of blood culture test products in this region. Stakeholders of this Research Report are as follows Study suggests that Abbott’s PCR/ESI-MS can detect bacteria, viruses, or fungi in a short span of time when the blood culture tests market are negative. Such technological advancements will significantly contribute towards the adoption of rapid diagnostic techniques among hospital laboratories and reference laboratories, which are major end users of these instruments. Get the Sample Copy of this research In addition, the growth of the blood culture tests market in North America is driven by technological advancements and increase in demand for rapid diagnostic techniques. Various market players are focusing on new product launches to expand their product portfolios and cater to their wide customer base. Key players in the blood culture tests market include Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Thermo Fisher Scientific, Inc. (U.S.), Cepheid, Inc. (U.S.), Nanosphere, Inc. (U.S.), Roche Diagnostics (Switzerland), Beckman Coulter (U.S.), Bruker Corporation (U.S.), IRIDICA (U.S.), and T2 Biosystems (U.S.). Click now for more Details, Queries, Other Information and Order this study “Blood Culture Tests Market by Method (Automated, Manual), Product (Consumables, Instrument), Technology (PCR, Microarray, Proteomic), Application (Bacteremia, Fungemia) & End User (Hospital Laboratories, Reference Laboratories) - Global Forecast to 2021” report @ http://www.reportsnreports.com/contacts/discount.aspx?name=377270 . Global blood culture tests market is dominated by North America, followed by Europe. However, market in Asia is expected to register the highest growth rate. Factors such as high incidence of sepsis and government initiatives to increase awareness on disease, increasing demand for effective diagnostic techniques, rising awareness about early disease diagnosis. Increasing adoption of advanced technologies, rapid rise in geriatric population, and growing regulatory approvals & availability of blood culture test products in this region are contributing to high growth rate of this market segment. Explore more reports on Healthcare at http://www.reportsnreports.com/market-research/healthcare/


News Article | November 17, 2016
Site: www.newsmaker.com.au

MarketStudyReport.com adds “2016 Global Blood Culture Tests Market Status, 2011-2022 Market Historical and Forecasts, Professional Market Research Report” new report to its research database. The report spread across 139 pages with table and figures in it. This New Version Blood Culture Tests Market Research Report is a deep market research report in this market. This report focused on global and regional market, major manufacturers, as well as the segment market details on different classifications and applications. First, this report analyzed the basic scope of this industry like definition, specification, classification, application, industry policy and news in Chapter 1. Second, the analysis on industry chain is provided including the up and down stream industry also with the major market players. And the analysis on manufacturing including process, cost structure and major plants distribution is conducted in Chapter 2. Then the global and regional market is analyzed. In these chapters, this report analyzed major market data like capacity, production, capacity utilization rate, price, revenue, cost, gross, gross margin, supply, import, export, consumption, market share, growth rate and etc. For regional market, this report analyzed major regions like Europe, North America, South America, Asia (Excluding China), China and ROW. These analysis are conducted in Chapter 3 and 4. In Chapter 5, the performance of major manufacturers are analyzed and then in Chapter 6 and 7 the analysis on major classification and application. Then the marketing channel analysis is provided including the major distributors in Chapter 8. Then this report analyzed the market forecast from 2017 to 2022 for global and regional market in Chapter 9 and the new project investment feasibility analysis in Chapter 10. At last, this report provided the conclusions of this research in Chapter 11. This report is a valuable source of guidance for manufacturers, suppliers, distributors, customers, investors and individuals who have interest in this market. Browse full table of contents and data tables at https://www.marketstudyreport.com/reports/2016-global-blood-culture-testsmarket-status-2011-2022-market-historical-and-forecasts-professional-market-research-report/ 5 Major Manufacturers Analysis 5.1 Becton, Dickinson and Company? 5.1.1 Company Profile 5.1.2 Product Specification 5.1.3 2011-2016 Global Market Performance 5.1.4 2015 Regional Market Performance 5.1.5 Contact Information 5.2 Biom?rieux SA? 5.2.1 Company Profile 5.2.2 Product Specification 5.2.3 2011-2016 Global Market Performance 5.2.4 2015 Regional Market Performance 5.2.5 Contact Information 5.3 Thermo Fisher Scientific, Inc.? 5.3.1 Company Profile 5.3.2 Product Specification 5.3.3 2011-2016 Global Market Performance 5.3.4 2015 Regional Market Performance 5.3.5 Contact Information 5.4 Cepheid? 5.4.1 Company Profile 5.4.2 Product Specification 5.4.3 2011-2016 Global Market Performance 5.4.4 2015 Regional Market Performance 5.4.5 Contact Information 5.5 Nanosphere, Inc.? 5.5.1 Company Profile 5.5.2 Product Specification 5.5.3 2011-2016 Global Market Performance 5.5.4 2015 Regional Market Performance 5.5.5 Contact Information 5.6 Bruker Corporation? 5.6.1 Company Profile 5.6.2 Product Specification 5.6.3 2011-2016 Global Market Performance 5.6.4 2015 Regional Market Performance 5.6.5 Contact Information 5.7 Beckman Coulter (Wholly Owned Subsidiary of Danaher Corporation)? 5.7.1 Company Profile 5.7.2 Product Specification 5.7.3 2011-2016 Global Market Performance 5.7.4 2015 Regional Market Performance 5.7.5 Contact Information 5.8 Roche Diagnostics (A Division of F. Hoffmann-La Roche Ltd.)? 5.8.1 Company Profile 5.8.2 Product Specification 5.8.3 2011-2016 Global Market Performance 5.8.4 2015 Regional Market Performance 5.8.5 Contact Information 5.9 Iridica (A Subsidiary of Abbott Laboratories)? 5.9.1 Company Profile 5.9.2 Product Specification 5.9.3 2011-2016 Global Market Performance 5.9.4 2015 Regional Market Performance 5.9.5 Contact Information 5.10 T2 Biosystems 5.10.1 Company Profile 5.10.2 Product Specification 5.10.3 2011-2016 Global Market Performance 5.10.4 2015 Regional Market Performance 5.10.5 Contact Information 5.11 5.11.1 Company Profile 5.11.2 Product Specification 5.11.3 2011-2016 Global Market Performance 5.11.4 2015 Regional Market Performance 5.11.5 Contact Information 5.12 5.12.1 Company Profile 5.12.2 Product Specification 5.12.3 2011-2016 Global Market Performance 5.12.4 2015 Regional Market Performance 5.12.5 Contact Information To receive personalized assistance write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150


News Article | December 2, 2016
Site: www.newsmaker.com.au

Wiseguyreports.Com Adds “Anti-Infective Drugs -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database This report studies Anti-Infective Drugs in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering By types, the market can be split into Antibiotic Antiviral Antifungal Others By Application, the market can be split into Hospital use Clinic Household Others By Regions, this report covers (we can add the regions/countries as you want) North America China Europe Southeast Asia Japan India Global Anti-Infective Drugs Market Professional Survey Report 2016 1 Industry Overview of Anti-Infective Drugs 1.1 Definition and Specifications of Anti-Infective Drugs 1.1.1 Definition of Anti-Infective Drugs 1.1.2 Specifications of Anti-Infective Drugs 1.2 Classification of Anti-Infective Drugs 1.2.1 Antibiotic 1.2.2 Antiviral 1.2.3 Antifungal 1.2.4 Others 1.3 Applications of Anti-Infective Drugs 1.3.1 Hospital use 1.3.2 Clinic 1.3.3 Household 1.3.4 Others 1.4 Market Segment by Regions 1.4.1 North America 1.4.2 China 1.4.3 Europe 1.4.4 Southeast Asia 1.4.5 Japan 1.4.6 India 8 Major Manufacturers Analysis of Anti-Infective Drugs 8.1 GlaxoSmithKline 8.1.1 Company Profile 8.1.2 Product Picture and Specifications 8.1.2.1 Type I 8.1.2.2 Type II 8.1.2.3 Type III 8.1.3 GlaxoSmithKline 2015 Anti-Infective Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.1.4 GlaxoSmithKline 2015 Anti-Infective Drugs Business Region Distribution Analysis 8.2 Merck 8.2.1 Company Profile 8.2.2 Product Picture and Specifications 8.2.2.1 Type I 8.2.2.2 Type II 8.2.2.3 Type III 8.2.3 Merck 2015 Anti-Infective Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.2.4 Merck 2015 Anti-Infective Drugs Business Region Distribution Analysis 8.3 Pfizer 8.3.1 Company Profile 8.3.2 Product Picture and Specifications 8.3.2.1 Type I 8.3.2.2 Type II 8.3.2.3 Type III 8.3.3 Pfizer 2015 Anti-Infective Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.3.4 Pfizer 2015 Anti-Infective Drugs Business Region Distribution Analysis 8.4 Novartis AG 8.4.1 Company Profile 8.4.2 Product Picture and Specifications 8.4.2.1 Type I 8.4.2.2 Type II 8.4.2.3 Type III 8.4.3 Novartis AG 2015 Anti-Infective Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.4.4 Novartis AG 2015 Anti-Infective Drugs Business Region Distribution Analysis 8.5 Gilead Sciences 8.5.1 Company Profile 8.5.2 Product Picture and Specifications 8.5.2.1 Type I 8.5.2.2 Type II 8.5.2.3 Type III 8.5.3 Gilead Sciences 2015 Anti-Infective Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.5.4 Gilead Sciences 2015 Anti-Infective Drugs Business Region Distribution Analysis 8.6 Abbott 8.6.1 Company Profile 8.6.2 Product Picture and Specifications 8.6.2.1 Type I 8.6.2.2 Type II 8.6.2.3 Type III 8.6.3 Abbott 2015 Anti-Infective Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.6.4 Abbott 2015 Anti-Infective Drugs Business Region Distribution Analysis 8.7 Wyeth 8.7.1 Company Profile 8.7.2 Product Picture and Specifications 8.7.2.1 Type I 8.7.2.2 Type II 8.7.2.3 Type III 8.7.3 Wyeth 2015 Anti-Infective Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.7.4 Wyeth 2015 Anti-Infective Drugs Business Region Distribution Analysis 8.8 Sanofi-Aventis 8.8.1 Company Profile 8.8.2 Product Picture and Specifications 8.8.2.1 Type I 8.8.2.2 Type II 8.8.2.3 Type III 8.8.3 Sanofi-Aventis 2015 Anti-Infective Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.8.4 Sanofi-Aventis 2015 Anti-Infective Drugs Business Region Distribution Analysis 8.9 Bristol-Myers Squibb 8.9.1 Company Profile 8.9.2 Product Picture and Specifications 8.9.2.1 Type I 8.9.2.2 Type II 8.9.2.3 Type III 8.9.3 Bristol-Myers Squibb 2015 Anti-Infective Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.9.4 Bristol-Myers Squibb 2015 Anti-Infective Drugs Business Region Distribution Analysis 8.10 Johnson 8.10.1 Company Profile 8.10.2 Product Picture and Specifications 8.10.2.1 Type I 8.10.2.2 Type II 8.10.2.3 Type III 8.10.3 Johnson 2015 Anti-Infective Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.10.4 Johnson 2015 Anti-Infective Drugs Business Region Distribution Analysis 8.11 Roche Pharma AG 8.11.1 Company Profile 8.11.2 Product Picture and Specifications 8.11.2.1 Type I 8.11.2.2 Type II 8.11.2.3 Type III 8.11.3 Roche Pharma AG 2015 Anti-Infective Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.11.4 Roche Pharma AG 2015 Anti-Infective Drugs Business Region Distribution Analysis 8.12 Nanosphere 8.12.1 Company Profile 8.12.2 Product Picture and Specifications 8.12.2.1 Type I 8.12.2.2 Type II 8.12.2.3 Type III 8.12.3 Nanosphere 2015 Anti-Infective Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.12.4 Nanosphere 2015 Anti-Infective Drugs Business Region Distribution Analysis 8.13 NanoViricides 8.13.1 Company Profile 8.13.2 Product Picture and Specifications 8.13.2.1 Type I 8.13.2.2 Type II 8.13.2.3 Type III 8.13.3 NanoViricides 2015 Anti-Infective Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.13.4 NanoViricides 2015 Anti-Infective Drugs Business Region Distribution Analysis 8.14 Novabay Pharmaceuticals 8.14.1 Company Profile 8.14.2 Product Picture and Specifications 8.14.2.1 Type I 8.14.2.2 Type II 8.14.2.3 Type III 8.14.3 Novabay Pharmaceuticals 2015 Anti-Infective Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.14.4 Novabay Pharmaceuticals 2015 Anti-Infective Drugs Business Region Distribution Analysis 8.15 Obetech 8.15.1 Company Profile 8.15.2 Product Picture and Specifications 8.15.2.1 Type I 8.15.2.2 Type II 8.15.2.3 Type III 8.15.3 Obetech 2015 Anti-Infective Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.15.4 Obetech 2015 Anti-Infective Drugs Business Region Distribution Analysis 8.16 Optimer Pharmaceuticals 8.16.1 Company Profile 8.16.2 Product Picture and Specifications 8.16.2.1 Type I 8.16.2.2 Type II 8.16.2.3 Type III 8.16.3 Optimer Pharmaceuticals 2015 Anti-Infective Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.16.4 Optimer Pharmaceuticals 2015 Anti-Infective Drugs Business Region Distribution Analysis 8.17 Basilea Pharmaceutica AG 8.17.1 Company Profile 8.17.2 Product Picture and Specifications 8.17.2.1 Type I 8.17.2.2 Type II 8.17.2.3 Type III 8.17.3 Basilea Pharmaceutica AG 2015 Anti-Infective Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.17.4 Basilea Pharmaceutica AG 2015 Anti-Infective Drugs Business Region Distribution Analysis 8.18 Daiichi Sankyo 8.18.1 Company Profile 8.18.2 Product Picture and Specifications 8.18.2.1 Type I 8.18.2.2 Type II 8.18.2.3 Type III 8.18.3 Daiichi Sankyo 2015 Anti-Infective Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.18.4 Daiichi Sankyo 2015 Anti-Infective Drugs Business Region Distribution Analysis 8.19 MerLion Pharma 8.19.1 Company Profile 8.19.2 Product Picture and Specifications 8.19.2.1 Type I 8.19.2.2 Type II 8.19.2.3 Type III 8.19.3 MerLion Pharma 2015 Anti-Infective Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.19.4 MerLion Pharma 2015 Anti-Infective Drugs Business Region Distribution Analysis 8.20 Theravance 8.20.1 Company Profile 8.20.2 Product Picture and Specifications 8.20.2.1 Type I 8.20.2.2 Type II 8.20.2.3 Type III 8.20.3 Theravance 2015 Anti-Infective Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.20.4 Theravance 2015 Anti-Infective Drugs Business Region Distribution Analysis


News Article | October 26, 2016
Site: www.nanotech-now.com

Abstract: Northwestern University nanoscientist Chad A. Mirkin has been awarded the 2016 RUSNANOPRIZE for his invention of spherical nucleic acids (SNAs), tiny structures used around the globe for medical diagnostics, therapeutics and research purposes. Mirkin received the international nanotechnology prize, worth 3 million rubles ($48,000), at an award ceremony held today (Oct. 26) in Moscow. An international award committee selected Mirkin as this year’s sole winner of the prize, recognizing his “SNAs and other medical, pharmacological and biotechnological materials and devices based upon them.” Also recognized is Nanosphere, a company co-founded by Mirkin, for successfully “applying the research into industrial production.” Nanosphere is now owned and operated by Luminex. The RUSNANOPRIZE is awarded to “scientists and researchers being authors of scientific and/or technological discovery in the field of nanotechnology.” The prize focuses on a different area of nanotechnology each year; this year’s prize is for research conducted in the fields of medicine, pharmacology and biotechnology. “This honor is important validation for what my research group and I have been trying to accomplish in the emerging area of nanomedicine and, more specifically, for the translation of our discoveries at Northwestern into commercial products,” Mirkin said. Mirkin is the George B. Rathmann Professor of Chemistry in the Weinberg College of Arts and Sciences and director of Northwestern’s International Institute for Nanotechnology. He also is a professor of medicine at Northwestern University’s Feinberg School of Medicine and professor of chemical and biological engineering, biomedical engineering and materials science and engineering in the McCormick School of Engineering. SNAs are structures composed of spherical nanoparticles densely covered with DNA or RNA — the genetic blueprints of living organisms. Similar to rays emitting from the sun, the DNA or RNA strands dangle from a common center; the resulting 3-D structure gives SNAs chemical and physical properties that are radically different from linear nucleic acids, the primary structure found in nature. SNAs can naturally enter human cells and tissues while conventional forms of DNA and RNA cannot. SNAs are the basis for a pipeline of drugs designed to treat a wide variety of human diseases, including psoriasis, diabetic wounds and many forms of cancer. RUSNANO established the RUSNANOPRIZE in 2009. RUSNANO implements state policy for the development of the nanoindustry in Russia, acting as a co-investor in nanotechnology projects that have substantial economic or social potential. For more information, please click If you have a comment, please us. Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.


Patent
Nanosphere | Date: 2012-12-18

The invention relates to methods for detecting complexes of Tau, Tau variants, including phosphorylated variants, and amyloid containing molecules, as well as autoantibodies to those complexes or components of those complexes, in physiological fluid samples.


An apparatus and method for imaging metallic nanoparticles is provided. Preferably, the invention provides for an apparatus and method for detection of gold colloid particles and for accurate reporting to the operator. The apparatus includes a substrate holder for holding the substrate, a processor and memory device, an imaging module, an illumination module, a power module, an input module, and an output module. The apparatus may have a stationary substrate holder and imaging module which are proximate to one another. The apparatus provided for a compact sized system without the need for complex motorized devices to move the camera across the substrate. Further, the apparatus and method provide for automatic detection of the spots/wells on the substrate, automatic quantification of the spots on the substrate, and automatic interpretation of the spots based on decision statistics.


This disclosure teaches phospholipid nanoparticle compositions of cannabinoids formed from phospholipids and simpler lipids in an unfired sequential process that encapsulate a high concentration of cannabinoids, and create standardized precision-metered dosage forms of cannabinoids; yielding an increase cannabinoid transport across hydrophobic mucosa; increase the bioavailability of the cannabinoid 2-fold to 8-fold, decrease the dose of cannabinoids 2-fold to 8-fold less than an amount of cannabinoids needed to illicit the same therapeutic effect compared to raw and non-encapsulated cannabinoids; where the nanoparticle dynamic structure reduces the adverse effects of cannabinoids; and enable safe more efficacious cannabinoid therapy.


A method includes applying ultrasound to a container having a plurality of magnetic particles contacted with a fluid sample having a biological material capable of binding to the magnetic particles, in an amount effective to suspend the magnetic particles in the fluid.


Patent
Nanosphere | Date: 2015-04-22

Disclosed are cartridges and modules that may be utilized in diagnostic systems and methods. The cartridge includes a flexible seal that caps the cartridge. The flexible seal has an opening for a pipette tip, and the flexible seal is configured to create a sealed environment when a pipette tip is positioned in the opening of the flexible seal and when the pipette tip is moved in the X-axis, Y-axis, and Z-axis.

Loading Nanosphere collaborators
Loading Nanosphere collaborators